TW202310874A - B7-h3抗體的藥物組合物及其用途 - Google Patents

B7-h3抗體的藥物組合物及其用途 Download PDF

Info

Publication number
TW202310874A
TW202310874A TW111126185A TW111126185A TW202310874A TW 202310874 A TW202310874 A TW 202310874A TW 111126185 A TW111126185 A TW 111126185A TW 111126185 A TW111126185 A TW 111126185A TW 202310874 A TW202310874 A TW 202310874A
Authority
TW
Taiwan
Prior art keywords
cancer
enoblituzumab
pharmaceutical composition
composition
container
Prior art date
Application number
TW111126185A
Other languages
English (en)
Chinese (zh)
Inventor
周岩
克里斯南 山帕斯庫瑪
史蒂芬詹姆士 柏克
王曉彥
Original Assignee
美商宏觀基因股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商宏觀基因股份有限公司 filed Critical 美商宏觀基因股份有限公司
Publication of TW202310874A publication Critical patent/TW202310874A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW111126185A 2021-07-16 2022-07-12 B7-h3抗體的藥物組合物及其用途 TW202310874A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
US63/222,750 2021-07-16

Publications (1)

Publication Number Publication Date
TW202310874A true TW202310874A (zh) 2023-03-16

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111126185A TW202310874A (zh) 2021-07-16 2022-07-12 B7-h3抗體的藥物組合物及其用途

Country Status (11)

Country Link
US (1) US20240336687A1 (cg-RX-API-DMAC10.html)
EP (1) EP4370155A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024526773A (cg-RX-API-DMAC10.html)
KR (1) KR20240038005A (cg-RX-API-DMAC10.html)
CN (1) CN117715657A (cg-RX-API-DMAC10.html)
AU (1) AU2022310668A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224118A1 (cg-RX-API-DMAC10.html)
IL (1) IL310187A (cg-RX-API-DMAC10.html)
MX (1) MX2024000690A (cg-RX-API-DMAC10.html)
TW (1) TW202310874A (cg-RX-API-DMAC10.html)
WO (1) WO2023288173A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
EP3714901A4 (en) * 2017-12-22 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20230041197A1 (en) * 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Il-5に対する抗体を含有する医薬組成物及びその使用
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
CN115103691B (zh) * 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途

Also Published As

Publication number Publication date
EP4370155A4 (en) 2025-06-11
WO2023288173A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
CA3224118A1 (en) 2023-01-19
MX2024000690A (es) 2024-02-07
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
CN117715657A (zh) 2024-03-15
IL310187A (en) 2024-03-01
EP4370155A1 (en) 2024-05-22
JP2024526773A (ja) 2024-07-19

Similar Documents

Publication Publication Date Title
JP5513380B2 (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
JP5918246B2 (ja) 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
CA2885862A1 (en) Stable, low viscosity antibody formulation
ES2668900T3 (es) Formulaciones estabilizadas que contienen anticuerpos anti-Dll4
KR20210114989A (ko) 치료 항체 제제
US11958906B2 (en) Pharmaceutical compositions of mosunetuzumab and methods of use
US20240336687A1 (en) Pharmaceutical compositions of a b7-h3 antibody and use of the same
CN119997972A (zh) 抗cd20抗体的药物组合物及其用途
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
US20230140384A1 (en) Antibodies to cd40 with enhanced agonist activity
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
HK40112469A (en) Pharmaceutical compositions of a pd-1 antibody and use of the same
RU2824627C2 (ru) Фармацевтическая композиция анти-cd20 антитела и ее применение
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40102521A (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
TW202128220A (zh) 穩定液體組合物、其製備方法及含有其之調配物
TR2025000822T2 (tr) Anti̇-cd20 anti̇kor farmasöti̇k bi̇leşi̇mi̇ ve bunun kullanimi
EA052238B1 (ru) Фармацевтическая композиция анти-cd20 антитела и ее применение
BR122025004506A2 (pt) Composições farmacêuticas compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo, método de preparação e usos das mesmas, bem como kit